Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net loss	$ (5,633,345)	$ (1,424,846)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	20,370	6,693
Change in fair value of warrant liability	(481,011)	(1,761,956)
Financing expense	14,636	88,939
Stock-based compensation	227,435	205,829
Accrued interest on CIRM award	264,827	0
Changes in assets and liabilities:
Other assets	185,052	(360,859)
Supplies for clinical trials	(356,182)	0
Deposits	413,402	0
Accounts payable	(249,821)	170,613
Accrued compensation and benefits	(575,079)	(186,951)
Accrued liabilities	818,795	213,552
Net cash used in operating activities	(5,350,921)	(3,048,986)
Cash flows from investing activities:
Purchase of property and equipment	(4,015)	(1,758)
Net cash used in investing activities	(4,015)	(1,758)
Cash flows from financing activities:
Proceeds from the issuance of common stock	264,668	0
Proceeds from issuance of common stock and warrants net of offering costs	0	14,599,627
Net cash provided by financing activities	264,668	14,599,627
Decrease in cash and cash equivalents	(5,090,268)	11,548,883
Cash and cash equivalents, beginning of period	22,604,481	23,222,296
Cash and cash equivalents, end of period	17,514,213	34,771,179
Supplemental cash flows disclosures:
Interest expense paid	0	0
Income taxes paid	0	0
Supplemental non-cash financing disclosures:
Deferred offering costs included in accounts payable	$ 8,593	$ 0